These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21112785)

  • 1. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.
    Probst GD; Bowers S; Sealy JM; Truong AP; Hom RK; Galemmo RA; Konradi AW; Sham HL; Quincy DA; Pan H; Yao N; Lin M; Tóth G; Artis DR; Zmolek W; Wong K; Qin A; Lorentzen C; Nakamura DF; Quinn KP; Sauer JM; Powell K; Ruslim L; Wright S; Chereau D; Ren Z; Anderson JP; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2011 Jan; 21(1):315-9. PubMed ID: 21112785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement.
    Neitz RJ; Konradi AW; Sham HL; Zmolek W; Wong K; Qin A; Lorentzen C; Nakamura D; Quinn KP; Sauer JM; Powell K; Ruslim L; Chereau D; Ren Z; Anderson J; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3726-9. PubMed ID: 21570836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1.
    Yao K; Cho YY; Bode AM; Vummenthala A; Park JG; Liu K; Pang YP; Dong Z
    FEBS Lett; 2009 Jul; 583(13):2208-12. PubMed ID: 19527717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
    Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
    Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
    Szczepankiewicz BG; Kosogof C; Nelson LT; Liu G; Liu B; Zhao H; Serby MD; Xin Z; Liu M; Gum RJ; Haasch DL; Wang S; Clampit JE; Johnson EF; Lubben TH; Stashko MA; Olejniczak ET; Sun C; Dorwin SA; Haskins K; Abad-Zapatero C; Fry EH; Hutchins CW; Sham HL; Rondinone CM; Trevillyan JM
    J Med Chem; 2006 Jun; 49(12):3563-80. PubMed ID: 16759099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3.
    Christopher JA; Atkinson FL; Bax BD; Brown MJ; Champigny AC; Chuang TT; Jones EJ; Mosley JE; Musgrave JR
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2230-4. PubMed ID: 19303774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JNK3 as a therapeutic target for neurodegenerative diseases.
    Antoniou X; Falconi M; Di Marino D; Borsello T
    J Alzheimers Dis; 2011; 24(4):633-42. PubMed ID: 21321401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
    Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
    J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2.
    Ansideri F; Dammann M; Boeckler FM; Koch P
    Anal Biochem; 2017 Sep; 532():26-28. PubMed ID: 28552758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR studies of 1,2-diaryl-1H-benzimidazole derivatives as JNK3 inhibitors with protective effects in neuronal cells.
    Kim MH; Ryu JS; Hah JM
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1639-42. PubMed ID: 23416008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting JNK3 for the treatment of neurodegenerative disorders.
    Resnick L; Fennell M
    Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-JUN N-terminal kinase-1 (JNK1) but not JNK2 or JNK3 is involved in UV signal transduction in human epidermis.
    Katagiri C; Negishi K; Hibino T
    J Dermatol Sci; 2006 Sep; 43(3):171-9. PubMed ID: 16824735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
    Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases.
    Hu MC; Qiu WR; Wang YP
    Oncogene; 1997 Nov; 15(19):2277-87. PubMed ID: 9393873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.
    Cao J; Gao H; Bemis G; Salituro F; Ledeboer M; Harrington E; Wilke S; Taslimi P; Pazhanisamy S; Xie X; Jacobs M; Green J
    Bioorg Med Chem Lett; 2009 May; 19(10):2891-5. PubMed ID: 19361991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Xue Y; Arzel E; Kallin E; Magnus A; Plobeck N; Viklund J
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1397-401. PubMed ID: 16337120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.